image
Healthcare - Medical - Devices - NASDAQ - US
$ 7.53
-0.406 %
$ 306 M
Market Cap
-11.14
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one RXST stock under the worst case scenario is HIDDEN Compared to the current market price of 7.53 USD, RxSight, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one RXST stock under the base case scenario is HIDDEN Compared to the current market price of 7.53 USD, RxSight, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one RXST stock under the best case scenario is HIDDEN Compared to the current market price of 7.53 USD, RxSight, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart RXST

image
$35.0$35.0$30.0$30.0$25.0$25.0$20.0$20.0$15.0$15.0$10.0$10.0$5.0$5.0Feb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '2515 Jul15 Jul
FINANCIALS
140 M REVENUE
57.09%
-36.9 M OPERATING INCOME
26.41%
-27.5 M NET INCOME
43.52%
-16.9 M OPERATING CASH FLOW
59.26%
-99.3 M INVESTING CASH FLOW
-348.78%
123 M FINANCING CASH FLOW
100.44%
37.9 M REVENUE
-5.77%
-10.7 M OPERATING INCOME
-23.71%
-8.19 M NET INCOME
-37.93%
-8.83 M OPERATING CASH FLOW
-107.32%
20.9 M INVESTING CASH FLOW
1479.92%
-735 K FINANCING CASH FLOW
-24.70%
Balance Sheet RxSight, Inc.
image
Current Assets 294 M
Cash & Short-Term Investments 237 M
Receivables 30 M
Other Current Assets 26.6 M
Non-Current Assets 24.7 M
Long-Term Investments 0
PP&E 23.6 M
Other Non-Current Assets 1.11 M
74.47 %9.43 %8.33 %7.42 %Total Assets$318.6m
Current Liabilities 25.9 M
Accounts Payable 4.54 M
Short-Term Debt 974 K
Other Current Liabilities 20.4 M
Non-Current Liabilities 11.4 M
Long-Term Debt 11.3 M
Other Non-Current Liabilities 127 K
12.17 %54.54 %30.33 %Total Liabilities$37.3m
EFFICIENCY
Earnings Waterfall RxSight, Inc.
image
Revenue 140 M
Cost Of Revenue 41 M
Gross Profit 98.9 M
Operating Expenses 136 M
Operating Income -36.9 M
Other Expenses -9.4 M
Net Income -27.5 M
140m140m120m120m100m100m80m80m60m60m40m40m20m20m00(20m)(20m)(40m)(40m)140m(41m)99m(136m)(37m)9m(27m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
70.71% GROSS MARGIN
70.71%
-26.34% OPERATING MARGIN
-26.34%
-19.62% NET MARGIN
-19.62%
-9.76% ROE
-9.76%
-8.62% ROA
-8.62%
-12.57% ROIC
-12.57%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis RxSight, Inc.
image
00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)(70m)(70m)202020202021202120222022202320232024202420252025
Net Income -27.5 M
Depreciation & Amortization 3.62 M
Capital Expenditures -5.44 M
Stock-Based Compensation 0
Change in Working Capital -9.21 M
Others -16.9 M
Free Cash Flow -22.4 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets RxSight, Inc.
image
Wall Street analysts predict an average 1-year price target for RXST of $68.1 , with forecasts ranging from a low of $52 to a high of $110 .
RXST Lowest Price Target Wall Street Target
52 USD 590.57%
RXST Average Price Target Wall Street Target
68.1 USD 804.71%
RXST Highest Price Target Wall Street Target
110 USD 1360.82%
Price
Max Price Target
Min Price Target
Average Price Target
120120100100808060604040202000Sep '24Sep '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 8
6. Ownership
Insider Ownership RxSight, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
289 K USD 2
6-9 MONTHS
1.98 M USD 2
9-12 MONTHS
2.96 M USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
1.11 M USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
RxSight, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – RXST LOS ANGELES--(BUSINESS WIRE)---- $RXST--RxSight, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – RXST. businesswire.com - 3 days ago
RXST Investors Have Opportunity to Join RxSight, Inc. Fraud Investigation with the Schall Law Firm LOS ANGELES , July 21, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of RxSight, Inc. ("RxSight" or "the Company") (NASDAQ: RXST) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. prnewswire.com - 4 days ago
RXST SECURITIES NEWS: Did RxSight, Inc. (NASDAQ:RXST) Commit Securities Fraud? Contact BFA Law about its Investigation into the Company NEW YORK, July 20, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into RxSight, Inc. (NASDAQ: RXST) for potential violations of the federal securities laws. If you invested in RxSight, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/rxsight-inc-class-action-lawsuit. globenewswire.com - 5 days ago
RXST Investors Have Opportunity to Join RxSight, Inc. Fraud Investigation with the Schall Law Firm LOS ANGELES--(BUSINESS WIRE)---- $RXST--RXST Investors Have Opportunity to Join RxSight, Inc. Fraud Investigation with the Schall Law Firm. businesswire.com - 6 days ago
RXST INVESTIGATION: RxSight, Inc. (NASDAQ:RXST) 38% Stock Drop Triggers Securities Fraud Investigation – Contact BFA Law if You Lost Money NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into RxSight, Inc. (NASDAQ: RXST) for potential violations of the federal securities laws. If you invested in RxSight, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/rxsight-inc-class-action-lawsuit. globenewswire.com - 1 week ago
RXST BREAKING NEWS: BFA Law is Investigating RxSight, Inc. for Securities Fraud; Contact the Firm about how to Potentially Recover Investment Losses NEW YORK--(BUSINESS WIRE)---- $RXST #Attorney--Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into RxSight, Inc. (NASDAQ: RXST) for potential violations of the federal securities laws. If you invested in RxSight, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/rxsight-inc-class-action-lawsuit. Why is RxSight being Investigated? RxSight is engaged in the manufacture and sale of light adjustable intraocular lenses use. businesswire.com - 1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc. - RXST NEW YORK , July 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ("RxSight" or the "Company") (NASDAQ: RXST).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. prnewswire.com - 1 week ago
Securities Fraud Investigation Into RxSight, Inc. (RXST) Continues – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, continues its investigation on behalf of RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON RXSIGHT, INC. (RXST), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On July 9, 2025, RxSight reported preliminary. businesswire.com - 1 week ago
RxSight, Inc. (RXST) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith continues its investigation on behalf of RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN RXSIGHT, INC. (RXST), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at how. businesswire.com - 1 week ago
RXSIGHT ALERT: Bragar Eagel & Squire, P.C.Announces Investigation into RxSight, Inc. (RXST) and Encourages Investors to Contact the Firm Bragar Eagel & Squire, P.C. Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In RxSight (RXST) To Contact Him Directly To Discuss Their Options globenewswire.com - 1 week ago
Robbins LLP is Investigating the Officers and Directors of RxSight, Inc. (RXST) to Determine if They Breached Fiduciary Duties Owed to Shareholders SAN DIEGO, July 15, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP is investigating RxSight, Inc. (NASDAQ: RXST) to determine whether certain RxSight, Inc. officers and directors violated securities laws and breached fiduciary duties to shareholders. RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. globenewswire.com - 1 week ago
Securities Fraud Investigation Into RxSight, Inc. (RXST) Continues – Investors Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON RXSIGHT, INC. (RXST), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is the Investigation About? On July 9, 2025, RxSight reported preliminary second quarter 2025 financial. businesswire.com - 1 week ago
8. Profile Summary

RxSight, Inc. RXST

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 306 M
Dividend Yield 0.00%
Description RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
Contact 100 Columbia, Aliso Viejo, CA, 92656 https://www.rxsight.com
IPO Date July 30, 2021
Employees 498
Officers Ms. Caroline Vaughn Vice President of Human Resources Mr. Roy Freeman Senior Vice President of Marketing & Professional Relations Dr. Ronald M. Kurtz M.D. Co-President, Chief Executive Officer & Director Mr. Scott Gaines Executive Vice President of Manufacturing & Commercial Operations Mr. Oliver Moravcevic Vice President of Investor Relations Mr. Matt Haller Ph.D. Chief Technology Officer Dr. Ilya Goldshleger Ph.D. Co-President & Chief Operating Officer Ms. Shelley B. Thunen Co-President & Chief Financial Officer Mr. Steve Everly Senior Vice President of Sales of North America Mr. Eric J. Weinberg Co-President & Chief Commercial Officer